MedTrace Logo

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

NCT07052877 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-07-11

No results posted yet for this study

Summary

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

Conditions

Interventions

DIAGNOSTIC_TEST

PSMA PET/CT scan

PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.

Sponsors & Collaborators

  • Royal North Shore Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • Australia

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07052877 on ClinicalTrials.gov